Purpose To estimate the rate of long-term lacosamide retention among a real-world group of
patients at a tertiary epilepsy center in Ireland. Methods One-hundred adults first prescribed …

INTRODUCTION: Lacosamide (LCS) is a new antiepileptic drug (AED) licensed in the
European Union (EU) and United States (US) in 2008. AIMS: To evaluate the efficacy and …

Lacosamide (LCM) is a recently licensed antiepileptic drug available in the UK since 2008. It
is thought to act through modulation of sodium channel slow inactivation. Its efficacy and …

Purpose Reporting of 'real-world'data on efficacy and tolerability of antiepileptic medications
helps to inform physicians on how newer medications perform in the clinical setting, outside …

Purpose We describe the effectiveness of lacosamide as adjunctive therapy in patients with
epilepsy and an intellectual disability. This information is relevant, as few data exist …

Summary Purpose In 2008, lacosamide (LCM) was licensed in Europe for the adjunctive
treatment of focal-onset seizures. At that time a prospective audit was initiated at the Western …

Abstract Purpose Lacosamide (LCM), the R-enantiomer of 2-acetamido-N-benzyl-3-
methoxypropionamide, is a newer approved antiseizure medication characterized by a …

Aims. To evaluate the safety and effectiveness of lacosamide in a real‐life setting with the
use of a flexible dose titration schedule and individualised maintenance doses up to the …

Objective Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of
partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients …

Purpose: Investigate the safety and tolerability of intravenous lacosamide (LCM) as
replacement for oral LCM in subjects with partial-onset seizures. Methods: 60 subjects …